ArticleAnnals of medicine2026
A treat-to-target urate management strategy does not improve kidney outcome in patients with chronic kidney disease and asymptomatic hyperuricemia: a target trial emulation.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gouty kidney disease: a tubulointerstitial paradigm reimagined-early detection, precision stratification, and targeted intervention.Rheumatology international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhether a treat-to-target urate management strategy improves kidney outcomes in patients with chronic kidney disease (CKD) and asymptomatic hyperuricemia initiating urate-lowering therapy (ULT) remains uncertain, despite current guidelines.
methodsThis target trial emulation (TTE) study included 2092 adults with stage G3-G4 CKD and asymptomatic hyperuricemia who initiated ULT at Zhejiang Provincial People's Hospital between 2018 and 2024. Using a clone-censor-weight (CCW) approach to address biases, we compared a treat-to-target strategy (targeting serum urate <360 μmol/L within 183 days) versus a non-treat-to-target strategy. Patients were followed for up to 3 years. The primary outcome was a composite kidney outcome: end-stage kidney disease (ESKD) or ≥40% eGFR decline.
resultsThe 3-year absolute risk of composite kidney outcome was 33.3% (95% CI, 30.1%-36.6%) under the treat-to-target strategy and 35.8% (95% CI, 30.7%-40.5%) under the non-treat-to-target strategy, yielding a risk difference of -2.5% (95% CI, -6.5% to 2.5%) and a risk ratio of 0.93 (95% CI, 0.83-1.08). Subgroup analyses revealed no heterogeneity, and sensitivity analyses yielded consistent results.
conclusionA treat-to-target urate management strategy was not associated with a reduced risk of composite kidney outcomes compared to a non-treat-to-target strategy. Among patients with stage G3-G4 CKD and asymptomatic hyperuricemia in whom clinicians decide to start ULT, these findings do not support pushing to achieve this intensive urate target for improving renal outcomes. As findings are largely based on a febuxostat-dominant real-world setting, extrapolation to other ULT agents may be limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.